Impax Labs Acquires Two Generic Products From Actavis

dpa-AFX International Compact |


WASHINGTON (dpa-AFX) - Impax Laboratories, Inc. (IPXL) announced that it has acquired two generic products from Actavis plc (ACT) for cash consideration pursuant to a Purchase Agreement and a Supply Agreement. Financial terms of the agreement were not disclosed.

The company said the acquisition includes one product marketed under an Abbreviated New Drug Application or ANDA - Ursodiol tablet - and one approved ANDA that is not yet marketed - Lamotrigine orally disintegrating tablet or ODT.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
WOLZY Woolworths Ltd. ADR (Sponsored) 144A n/a n/a n/a 0

Comments

Emerging Growth

GSV Capital Corp

GSV Capital Corp is an externally managed, non-diversified closed-end management investment company. The Company has elected to be treated as a business development company.

Private Markets

8tracks

Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…